<p>Interferon Alfa-2a is contraindicated in</p>

<ul>
	<li>patients with a history of hypersensitivity to recombinant interferon alfa-2a or any component of the preparation.</li>
	<li>patients with severe pre-existing cardiac disease or with any history of cardiac illness. No direct cardiotoxic effect has been demonstrated, but it is likely that acute, self-limiting toxicities (e.g. fever, chills) frequently associated with administration of Interferon Alfa-2a may exacerbate pre-existing cardiac conditions.</li>
	<li>severe renal, hepatic or myeloid dysfunction.</li>
	<li>seizure disorders and/or compromised central nervous system function.</li>
	<li>chronic hepatitis with advanced, decompensated hepatic disease.</li>
	<li>chronic hepatitis patients who are being or have recently been treated with immunosuppressive agents, excluding short-term &quot;steroid withdrawal&quot;.</li>
	<li>CML patients with an HLA-identical relative who are potential candidates for allogeneic bone marrow transplantation in the immediate future.</li>
	<li>neonates, children up to 3 years, and premature infants. Interferon Alfa-2a solution for injection contains benzyl alcohol. There have been reports of permanent neuropsychiatric deficits and multiple system organ failure associated with benzyl alcohol.</li>
</ul>